Novartis headquarters in Basel, Switzerland (Kyle LaHucik for Endpoints News)

No­var­tis’ Kisqali pre­vents breast can­cer from com­ing back for longer — but can it best Eli Lil­ly’s Verzenio? #AS­CO23

CHICA­GO — No­var­tis’ CDK4/6 in­hibitor Kisqali helped ear­ly breast can­cer pa­tients stay can­cer-free for longer af­ter surgery, ac­cord­ing to in­ter­im study re­sults pre­sent­ed at AS­CO.

In a Phase III study, Kisqali was added on top of en­docrine ther­a­py — the cur­rent stan­dard treat­ment for ear­ly breast can­cer pa­tients. Kisqali re­duced the risk of dis­ease re­lapse by 25% com­pared with en­docrine ther­a­py alone in pa­tients with Stage II or III HR-pos­i­tive, HER2-neg­a­tive breast can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA